Congress splits health agency oversight: three new watchdogs for NIH, CDC, FDA
S. 1607 — INSPECT Act · Filed by Eric Schmitt (R-MO) · Introduced May 6, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates three new independent Inspector General offices within the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. Each agency will have its own IG (currently they share one IG under HHS) to conduct audits, investigations, and oversight. The bill requires the President to appoint these IGs within one year and funds them by redirecting existing HHS-IG budget, not by requesting new money.
Why we flagged it
The bill's sole operative mechanism is the creation of three independent Inspector General offices within health agencies. This is a structural reform aimed at strengthening internal oversight and accountability, not a policy change or appropriation.
What the text implies
- Splitting the HHS-IG office into four separate entities (HHS proper + NIH + CDC + FDA) may reduce the shared IG's capacity to investigate cross-agency issues or coordinate oversight of HHS-wide programs.
- The bill requires appointment within one year but does not specify qualifications, confirmation process, or removal protections beyond what 5 U.S.C. § 403(a) provides — the actual independence of these IGs depends on statutory language not quoted here.
- Funding from existing HHS-IG budget means the three new IGs will compete with the parent HHS-IG for resources; no new money is authorized, so total oversight capacity may not increase despite structural separation.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Citizens gain independent oversight of three major health agencies (NIH, CDC, FDA) that directly affect public health, drug safety, and research integrity. Separate IGs can focus resources and pursue investigations without competing priorities, improving accountability and transparency in agencies that regulate medicines, vaccines, and public health policy.
Named in the bill
National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), Department of Health and Human Services (HHS), Office of the Inspector General, 5 U.S.C. § 401, 5 U.S.C. § 403(a)
Where it stands
- May 6, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- May 6, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (1,761 characters) on Sep 23, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 14,707 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-09-23.
“Congress splits health agency oversight: three new watchdogs for NIH, CDC, FDA” QuorumCivic. https://share.quorumcivic.app/bill/119/s1607 Report an error